This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
by Zacks Equity Research
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
Why Novartis (NVS) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
by Zacks Equity Research
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
by Zacks Equity Research
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
by Zacks Equity Research
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
Here's Why Novartis (NVS) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies
by Zacks Equity Research
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
by Zacks Equity Research
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
AstraZeneca (AZN) Discontinues Brazikumab Development
by Zacks Equity Research
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
by Zacks Equity Research
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
by Zacks Equity Research
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
5 Large Drug Stocks to Watch From a Thriving Industry
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
by Zacks Equity Research
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
by Zacks Equity Research
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.
Time to Buy Stock in These Pharmaceutical Giants for EPS Growth
by Shaun Pruitt
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Alimera (ALIM) Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
by Zacks Equity Research
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
Zacks.com featured highlights W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis
by Zacks Equity Research
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
Novo Nordisk (NVO) Announces Positive Obesity Program Data
by Zacks Equity Research
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Invest in These Dividend Growth Stocks Amid Default Fears
by Sweta Killa
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.